1	Genomic reconstruction of an azole-resistant Candida parapsilosis
2	outbreak and the creation of a multilocus sequence typing scheme
3	
4	
5	Running title: Genomic epidemiology and sequence typing of Candida parapsilosis
6	
7	
8	
9	
10	
11	Phillip Brassington ¹ , Frank-Rainer Klefisch ² , Barbara Graf ³ , Roland Pfüller ⁴ , Oliver Kurzai ^{5,6} , Grit
12	Walther ⁵ , Amelia E. Barber ¹
13	
14	
15	Address correspondence to: Amelia E. Barber (amelia.barber@uni-jena.de) or Grit Walther
16	(grit.walther@leibniz-hki.de)
17	
18	
19	¹ Institute for Microbiology. Friedrich Schiller University Jena. Jena, Germany. ² Paulinen Hospital. Berlin, Germany.
20 21	³ Labor Berlin, Berlin, Germany.
22	⁴ MVZ Hauptstadtlabor, Labservice GmbH. Berlin, Germany.
23 24	⁵ National Reference Center for Invasive Fungal Infections (NRZMyk). Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute. Jena, Germany.

⁶ Institute for Hygiene and Microbiology. University of Würzburg. Würzburg, Germany.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Abstract

27 Background

28 Fluconazole-resistant *Candida parapsilosis* has emerged as a significant healthcare-associated

29 pathogen with a propensity to spread patient-to-patient and cause nosocomial outbreaks, similar to

- 30 *Candida auris*. This study investigates a prolonged outbreak of fluconazole-resistant *C. parapsilosis*
- across multiple years and healthcare centers in Germany.
- 32
- 33 <u>Methods</u>
- 34 We employed whole-genome sequencing of isolates from the outbreak, other regions within
- 35 Germany, and compared them with isolates from a global distribution to understand the molecular
- ³⁶ epidemiology of this outbreak. Additionally, we used the genomic dataset of 258 samples to identify
- loci with high discriminatory power to establish the first multi-locus sequence typing (MLST) strategy
 for *C. parapsilosis*.
- 39

40 <u>Findings</u>

A clonal, azole-resistant strain of *C. parapsilosis* was observed causing invasive infections over multiple years and in multiple hospitals within the outbreak city. Including this outbreak clone, we identified three distinct *ERG11* Y132F azole-resistant lineages in Germany, marking the first description of this azole-resistance in the country and its endemic status. Using the novel MLST strategy, isolates were categorized into 31 sequence types, proving the utility of the typing scheme for genetic epidemiology and outbreak investigations as a rapid alternative to whole genome sequencing.

48

49 Interpretation

Temporal and genomic reconstruction of the outbreak indicated that transfer of patients between 50 healthcare facilities was likely responsible for the persistent reimportation of the drug-resistant clone 51 and subsequent person-to-person transmission. This research underscores the importance of 52 53 monitoring of C. parapsilosis epidemiology, not only in Germany but globally. The emergence of 54 azole-resistant lineages necessitates continuous surveillance and rigorous infection control 55 measures. By combining large-scale genomic epidemiology and introducing a novel typing method, our study offers valuable insights into the management of emerging healthcare-associated 56 pathogens, with direct implications for public health and clinical practice. 57

- 58
- 59 <u>Funding</u>

60 German Federal Ministry for Education and Research, German Research Foundation, German

61 Ministry of Health

62 Research in Context

63 Evidence before this study

The epidemiology of candidemia has undergone dramatic changes in recent years. New pathogenic species, such as *Candida auris*, have emerged, and existing species like *Candida parapsilosis* have increased in prominence. There has also been a worrying increase in drug resistance among *Candida* species. Moreover, numerous drug-resistant outbreaks of *C. parapsilosis* have been reported worldwide and are challenging to control due to their prolonged and intermittent nature. The evidence sources considered for this study were journal articles found through the search terms "Candida parapsilosis", "outbreak", "azole resistance", and/or "fluconazole" in PubMed and Google Scholar.

71

72 Added value of this study

This study adds to the existing evidence by utilizing whole genome sequencing in conjunction with 73 74 hospital records to analyze a prolonged outbreak of clonal, azole-resistant C. parapsilosis that 75 occurred across multiple years and medical centers. This study demonstrates that patient transfers 76 can result in the reimportation of outbreak clones, posting a significant challenge for infection control. 77 We also reveal that the outbreak clone is closely related to drug-resistant isolates from other continents, highlighting the global spread of drug-resistant C. parapsilosis. Furthermore, the study addresses the need for 78 rapid strain differentiation in outbreak settings by establishing and validating a set of four loci for 79 sequence-based typing, which provide a highly discriminatory tool for epidemiologic investigations. 80

81

82 Implications of all the available evidence

This study underscores the global challenge of azole-resistant *C. parapsilosis* and its importance as 83 the causative agent of nosocomial outbreaks. Clinicians should be aware of the evolving epidemiology 84 of C. parapsilosis and the prevalence of drug-resistant strains, emphasizing the importance of 85 appropriate antifungal stewardship and infection control measures. The study emphasizes the 86 challenges caused by inter-hospital transmission and their role in persistent outbreaks, highlighting 87 the need for robust surveillance and coordination among healthcare facilities. Furthermore, the 88 89 establishment of a sequence-based typing scheme is a valuable tool for rapid assessment of outbreak 90 clones, which can aid in outbreak tracking and containment efforts.

Introduction 91

During the last decade, the epidemiology of candidemia has seen dramatic changes due to the 92 emergence of new pathogenic species like Candida auris, and dramatic increases in the prominence 93 of existing species such as Candida parapsilosis ¹⁻⁴. C. parapsilosis is now the second to fourth 94 leading cause of systemic Candida infections and has gone from being historically associated with 95 pediatric infection to a frequent cause of catheter-associated bloodstream infections in adults². A 96 worrying accompaniment to the changing species epidemiology is a corresponding increase in drug 97 resistance in Candida spp. including C. parapsilosis. Previously, isolates of C. parapsilosis were 98 overwhelmingly azole susceptible. Now, there are more than 36 studies from 15 countries 99 documenting local fluconazole resistance rates of >10% in C. parapsilosis and an exponential 100 increase in reports of fluconazole-resistant C. parapsilosis since 2019⁴. Fluconazole-resistant 101 invasive disease results in a three-fold increase in mortality compared to infection with a susceptible 102 strain (16% for susceptible to 50% resistant infections)⁵. The most dominant fluconazole resistance 103 mechanism seen clinically is the Y132F amino acid substitution in the azole target gene, lanosterol14-104 105 alpha-demethylase (ERG11). This mutation has been reported in every country where fluconazoleresistant C. parapsilosis has been reported. Other resistance mutations, including additional 106 substitutions in ERG11 (e.g. K128N, K134R, G458S), as well as gain-of-function mutations in the 107 transcription factors MRR1 and TAC1 have also been observed clinically, but are less common ⁶⁻⁸. 108

109

Alongside the rapid increase in fluconazole resistance, there has been an alarming number of drug-110 resistant outbreaks of *C. parapsilosis* reported in the last ~5 years $^{5,9-18}$. This organism is commonly 111 found on the skin, and, as a result, it can spread within healthcare facilities in a patient-to-patient 112 manner through contaminated medical devices, environmental surfaces, or the hands of healthcare 113 workers ^{10,14,19}. Outbreaks of *C. parapsilosis* can also persist despite strict infection control strategies 114 and may show gaps in the occurrence of outbreak strains ^{4,20}. Recognition of nosocomial outbreaks 115 and implementation of successful infection control measures requires a rapid and reproducible 116 method for discriminating closely related isolates. However, there is currently no gold standard for 117 strain typing in C. parapsilosis. Currently, the most widely used method is a species-specific set of 118 microsatellite markers²¹. However, microsatellite typing requires specialized equipment, is prone to 119 PCR artifacts, and requires specialized knowledge for interpretation ^{22,23}. Moreover, microsatellite-120 based typing results are not as easily shared and compared across centers. Whole genome 121 sequencing (WGS) has exceptional resolution for discriminating between closely related isolates and 122 is incredibly valuable for outbreak investigation, as has been demonstrated for *C. auris*^{24–26}. However, 123 WGS is not feasible for many settings due to its cost, time to result, and limitations in trained personnel 124 to analyze the data. As demonstration of this, to our knowledge there is no large-scale, genome-level 125 analysis of a C. parapsilosis outbreak, despite their increasing frequency. 126

127

In this study we report an azole-resistant outbreak caused by Y132F C. parapsilosis that occurred in 128 Berlin, Germany across several years and medical centers. We use a large-scale genomic dataset 129

composed of 258 *C. parapsilosis* isolates to investigate outbreak dynamics, confirm the high degree
 of relatedness among outbreak isolates, and compare them to isolates from around the world. Finally,
 we leverage this genome collection to identify and validate four markers for Sanger sequence-based

- 133 strain typing, epidemiology, and rapid differentiation of isolates in future outbreaks.
- 134

135 **Results**

136 Clinical case description and outbreak reconstruction

We report a prolonged outbreak of *Candida parapsilosis* that occurred across multiple healthcare 137 institutions across Berlin, Germany during the period of 2018 - 2022 (Figure 1a). Cases were initially 138 detected by physicians at Hospital #1 (name anonymized for privacy), who recognized an increase in 139 isolates with a distinct antifungal susceptibility profile in their facility. The isolates were resistant to 140 fluconazole (FLC^R) and voriconazole (VOR^R), but susceptible to other triazoles. After a period of 141 approximately five months, during which no FLC^R and VOR^R infections were reported, infection 142 isolates with this susceptibility profile were once again observed at Hospital #1. The outbreak was 143 144 officially declared at that time (October 2019), and was formally investigated including environmental surveillance. As C. parapsilosis is known to colonize the ear, 21 ICU patients at Hospital #1 were 145 screened with swabs of both ears, but none were positive for C. parapsilosis. To investigate possible 146 transfer by staff, sixteen bedside stethoscopes were screened. Only one sample was positive, but the 147 resulting isolate of C. parapsilosis was azole susceptible. In addition, opened and sealed hand creams 148 used by staff were screened, but the pathogen was not detected. Hand sampling of staff was not 149 performed as this is discouraged in Germany due to stigmatization. 150

151

To prevent further cases, emphasis was placed on hygiene measures and particularly hand 152 disinfection. Following implementation of the infection control measures, there was a nine month 153 period without FLC^R and VOR^R strains reported. However, additional cases were detected in 154 September 2021 and the start-stop pattern continued through 2022 (Fig 1a). Consultations with other 155 hospitals and clinical laboratories in Berlin as well as the National Reference Center for Invasive 156 157 Fungal Infections (NRZMyk) identified C. parapsilosis infections with this same antifungal susceptibility profile at five other institutions around Berlin. Subsequent epidemiological and genomic 158 investigations revealed a total of 33 outbreak cases that are analyzed in the rest of this manuscript. 159 The majority of outbreak cases were first reported as wound infections (39%), followed by infections 160 associated with central venous catheters (29%) (Table 1). Outbreak isolates were all resistant to 161 fluconazole with a median minimum in inhibitory concentration (MIC) of 64 mg/l and voriconazole 162 (median MIC 1 mg/l), but susceptible to itraconazole (median MIC 0.125 mg/l) and posaconazole 163 (median MIC 0.03 mg/l) (Table 1). 164

165

To understand the transmission dynamics of the outbreak, we reconstructed the temporal and spatial relationship of the outbreak using admission and discharge records. The reconstruction of inpatient admissions and transfers between medical centers in Berlin revealed that even though the largest

fraction of outbreak cases (n = 20) were diagnosed at Hospital #1, the majority of these patients had 169 been directly transferred to this facility from a major surgical facility (indicated as Hospital #0 in Figure 170 1b). Supporting nosocomial transmission, the majority of outbreak cases (31/33; 94%) had verifiable. 171 temporal overlap with other cases, i.e. inpatient stays at a given hospital whose dates overlapped 172 with >one other outbreak patient (Figure 1b). Despite lacking specific ward information for all outbreak 173 cases, seven patient clusters involving a total of 22 patients had demonstrated spatial and temporal 174 overlap, with outbreak patients confirmed to have been on the same ward at the same time as other 175 outbreak cases, strongly supporting patient-to-patient spread (Figure 1b). In summary, we report a 176 multiyear, sporadic outbreak of azole-resistant C. parapsilosis in Germany that was not limited to any 177 single hospital but involved a network of hospitals in Berlin. 178

179

<u>Genomic epidemiology of *C. parapsilosis* confirms the clonal nature of Berlin outbreak strains and</u>
 reveals the presence of the outbreak strain on additional continents.

To define the genomic epidemiology of C. parapsilosis in Germany and examine the genomic 182 183 relationship between the putative outbreak cases from the hospitals in Berlin, we performed whole genome sequencing (WGS) on 68 isolates (33 outbreak isolates; 33 non-outbreak isolates) collected 184 by the German National Reference Centre for Invasive Fungal Infections (NRZMyk) between 2016 185 and 2022. Sequenced isolates originated from 29 medical centers in 16 cities. 64% (n = 44) of the 186 sequenced samples originated from Berlin, including samples suspected to be part of a local outbreak 187 and 14 non-linked isolates from different medical centers. Publicly available sequence data for an 188 additional 190 samples was also included to facilitate comparison of the German sequenced isolates 189 with the global C. parapsilosis population, bringing the total number of samples in the dataset to 258 190 genomes. WGS samples analyzed had a mean depth of coverage of 146x (range 10-248x) after data 191 quality control and mapping (Supplemental File 1). 192

193

When built into a whole genome phylogeny, samples from Germany were distributed throughout the 194 tree, with no phylogenetic group being unique to a specific country or continent (Figure 2). The close 195 196 genetic relationship between the outbreak strains was evident by their tight grouping and short branch lengths in the phylogeny, supporting the nosocomial transmission that was inferred from the spatial 197 and temporal overlap in cases (Figure 1b). The guasi-clonal relationship between outbreak isolates 198 was further confirmed by pairwise single nucleotide variant (SNV) analysis, where isolates in the 199 Berlin outbreak clade differed by an average of 36 SNVs (Figure 3). In contrast, the average number 200 of SNVs between non-outbreak isolates from other locations in Germany was significantly higher at 201 2,079 SNVs (p < 0.001 by student's t-test). Further, the number of SNVs observed between duplicate 202 sequencing of the same freezer stock of an isolate strain was 15 SNVs, indicating that the number of 203 pairwise SNV differences between repeat sequencing of the same sample was similar to the genetic 204 differentiation observed between different outbreak isolates. Strikingly, the public sequence data 205 revealed samples from Turkey, South Korea, and Kuwait that were closely related to the outbreak 206 strains from Berlin (Figure 2). These isolates were also reported to be fluconazole resistant ²⁷⁻²⁹, 207

highlighting the global spread of azole-resistant *C. parapsilosis*. These tightly related global strains
differed from the Berlin outbreak strains by an average of 96 SNVs (range 18-191), compared to the
mean 36 SNVs that the Berlin cluster differed from each other on average. Altogether, whole genome
sequencing confirmed the close genetic relationship of the outbreak strains and its presence of this
lineage in multiple other countries.

213

214 <u>ERG11 Y132F is the primary azole resistance mechanism among C. parapsilosis strains from</u> 215 <u>Germany</u>

Of the 68 German isolates newly described and sequenced in this study, 65% were resistant to one 216 or more triazole (n = 44) (Supplemental File 1). ERG11 Y132F was the dominant resistant 217 mechanism, with 36 resistant isolates possessing this mutation (n = 31 outbreak; n = 5 non-outbreak). 218 Interestingly, the non-outbreak Y132F strains were in two distantly related groups of samples based 219 220 on the phylogeny (Figure 2; Supplemental Figure 1). Each of these Y132F-containing phylogenetic 221 groups contained isolates from geographically distant regions of Germany, suggesting that there are at least 3 genomically-distinct lineages of Y132F C. parapsilosis circulating widely throughout the 222 country. 223

224

We also observed three closely related but unlinked samples from different cities in Germany that 225 were pan-azole resistant and carried a G458S substitution in ERG11 (Figure 2; Supplemental Figure 226 1) that has been linked to clinical pan-azole resistance previously ^{12,18,30,31}. Also included in our dataset 227 were eight isolates that were resistant to one more azoles, but did not contain any resistance-228 associated polymorphisms in ERG11. However, these isolates contained sequence polymorphisms 229 in several genes that have been linked to drug resistance, including the efflux pumps MDR1 and 230 CDR1B, the multidrug resistance gene regulator MRR1, and the transcriptional activator TAC1 231 (Supplemental Table 1). While a casual role for most of these polymorphisms in drug resistance have 232 not been experimentally established, one resistant isolate harbored a L518F substitution in TAC1 233 experimentally proven to confer azole resistance⁸. Among our newly described isolates and the public 234 235 genomes we observed additional amino acid polymorphisms in ERG11 present in susceptible strains, including M178T, N283Y, and both resistant and susceptible strains R398I ^{32–34}. Together, we find 236 that ERG11 Y132F is the dominant resistant mechanism among both outbreak and non-outbreak 237 238 fluconazole-resistant strains in Germany and, surprisingly, discover that our outbreak strains are closely related to resistant samples previously described from East and West Asia. 239

240

241 Identification of markers for multilocus typing in *C. parapsilosis*

As outbreaks of *C. parapsilosis* are being increasingly reported, there is an urgent need for a rapid and reproducible tool capable of differentiating isolates. Motivated by this, we set out to identify a minimal set of loci that could be used for Sanger sequence-based typing of both general epidemiology and outbreak detection. Based on the whole genome phylogeny, we identified 14 distinct genetic clusters of *C. parapsilosis* in our dataset of 258 genomes (Figure 4a, b). The clusters contained an

average of 17 samples (range 2-105) and were numbered to be concordant with the five major clades
 of *C. parapsilosis* described in ³⁵.

249

To identify loci with high discriminatory power, we performed a genome-wide screen of genetic variant 250 profiles first using full-length gene coding sequences, followed by 750 bp regions of CDS with the 251 high discriminatory power, and finally assessing these loci in combination. Using this approach, we 252 identified four 750 bp loci in CPAR2 101470, CPAR2 108720, CPAR2 212940, and CPAR2 808110 253 (Table 2) that were capable of differentiating isolates into 31 unique sequence types with a Hunter's 254 255 Discriminatory Power of 0.87. As C. parapsilosis is a diploid organism, an appreciable fraction of the discriminatory power comes from accounting for whether observed sequence polymorphisms were 256 heterozygous or homozygous. When nucleotide zygosity was not considered, we were only able to 257 identify 22 sequence types and the discriminatory power was reduced to 0.81. The four selected loci 258 259 showed a high degree of agreement with the whole genome phylogeny. Our typing scheme was able 260 to correctly identify samples to their whole genome-defined genetic cluster with 97.6% sensitivity and 261 99.9% specificity and a phylogeny created from loci sequence largely replicated the structure of the whole genome tree (Figure 4c). To confirm that the selected loci were present as a single copy and 262 the discriminatory power was not being inflated by the presence of multiple copies in the genome, we 263 assessed them for genome-wide copy number changes. Using three different copy number variation 264 softwares, we did not detect any CNV changes in these loci, either additional copies or loss of the 265 region (Supplemental Figure 2). Based on orthology with Candida albicans and Saccharomyces 266 cerevisiae, the identified loci have putative functions in the cytoskeleton, cell wall organization, and 267 ion transport (Table 2). 268

269

270 Laboratory validation of *in silico*-identified markers

To validate our *in silico* typing, we designed primers to PCR amplify the four identified loci (Table 3). 271 Using a representative 14 samples from our dataset, including four outbreak strains expected to have 272 identical sequence type profiles, we amplified and Sanger sequenced the four loci. In each sample, 273 274 we detected the expected variants from the in silico analysis by Sanger sequencing and did not 275 discover any variants that were not in the whole genome data (Supplemental Table 2). Resultantly, 276 we could correctly assign samples to the nine unique sequence types predicted from the in silico typing and the six genetic clusters assigned to them by the whole genome phylogeny. As expected, 277 the four outbreak samples had identical sequences at all four loci and were assigned to the same 278 sequence type. An important note is that Sanger sequencing providers may not report dual peaks 279 caused by heterozygous sites using IUPAC nucleotide codes. As this was the case for us, this was 280 resolved by manually recoding positions in the chromatograms where equal sized dual peaks were 281 recorded (for example, a double peak reporting an A and a G were recoded to the corresponding 282 IUPAC base of R). To facilitate the typing of novel isolates by future researchers and clinical labs, 283 FASTA alignments containing nucleotide sequence from each sequence type of each of the four 284 makers are provided in Supplemental File 2. 285

medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24302918; this version posted February 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

286

287 Demonstration of the utility of the typing scheme for rapidly identifying outbreak clones

To demonstrate the value of our typing scheme for the rapid identification of clones within an outbreak 288 setting, we tested our typing loci on a set of seven novel isolates that were not part of the dataset 289 used to create the typing scheme. These isolates were collected from three hospitals in Berlin and 290 were suspected to be additional outbreak cases based on their antifungal susceptibility profile (FLC^R, 291 VOR^R, POS^S, ITR^S) and their isolation from hospitals with previous outbreak cases. PCR amplification 292 and Sanger sequencing of the four typing loci revealed that their sequence type was identical to the 293 294 outbreak isolates analyzed by WGS, and strongly suggesting that they were additional outbreak cases (Supplemental Table 2). Taken together, we selected and validated four loci that can be used for 295 sequence-based typing of C. parapsilosis and demonstrated their value in rapidly identifying closely 296 297 related samples.

298

299 Discussion

300 In this work, we use genomic epidemiology coupled with patient tracking to investigate an outbreak of azole-resistant *C. parapsilosis* that occurred across several years and medical centers in Berlin, 301 Germany. C. parapsilosis is an emerging pathogen and our report joins the increasing list of 302 nosocomial outbreaks reported for this pathogen. Similar to Candida auris, this pathogen is often 303 drug resistant and has the propensity to spread patient-to-patient. Due to slow outbreak kinetics and 304 305 the low case density, the outbreak we describe might have gone unnoticed if not for the atypical susceptibility pattern that was detected by clinicians and clinical microbiologists. Based on the 306 increasing number of outbreaks for C. parapsilosis around the globe and the need to rapidly 307 discriminate between isolates, we also establish and validate a set of four loci for sequence-based 308 strain typing. 309

310

The reconstructed transmission dynamics suggest that persistent outbreaks of C. parapsilosis may 311 result from the reintroduction of outbreak strains from other hospitals, underlining the myriad 312 313 complex challenges of outbreak control and the need for heightened infection control measures. In 314 our case, patient transfers were a common occurrence among cases and facilitated inter-hospital 315 transmission and subsequent intra-hospital transmission. Unfortunately, the high-resolution 316 temporal and spatial monitoring of patients is lacking for other outbreak descriptions, so it is unclear the degree to which this has driven other reported C. parapsilosis outbreaks. However, the pattern 317 of prolonged but tightly related isolates causing disease across several years and multiple medical 318 centers matches other outbreak reports from France, Spain, China, and Brazil ^{15,17,31,36}, suggesting 319 that reintroductions and/or patient transfers could have also contributed to the prolonged nature of 320 these outbreaks. One limitation to our study is that while patients without infection were screened 321 for colonization during the first wave of cases at Hospital #1, a comprehensive screening of all the 322 involved hospitals and throughout the extended period of the outbreak was not performed. This 323 324 obscures an understanding of the relationship between colonization and subsequent infection

during the outbreak and a mechanistic understanding of how *C. parapsilosis* is transmitted within healthcare facilities.

327

The finding of azole-resistant strains from Turkey, South Korea, and Kuwait that were very closely 328 related to the strains spreading within healthcare facilities in Berlin highlights the global challenge of 329 antifungal resistance and the emergence of resistant Candida spp that are easily transmitted from 330 patient-to-patient. Whether this drug-resistant lineage has been present in each of these regions for 331 a longer period or was recently imported is an open question. We also cannot deduce whether it 332 333 was originally imported to Germany from any of these sites. The observation of highly related, drug resistant clones observed on multiple continents mirrors the behavior of Candida auris. Nearly 334 identical clades of this pathogen have been reported on multiple continents and continue to spread 335 globally ^{37,38}, underscoring the fact that *C. parapsilosis* has the potential to become a problem of 336 similar scale. Additionally, three phylogenetically distinct Y132F lineages of fluconazole-resistant 337 C. parapsilosis were discovered in Germany during the study period, each with multiple isolates 338 339 reported from distinct geographic areas. This demonstrats that fluconazole-resistant C. parapsilosis is endemic in Germany, mirroring what has been recently reported in other countries⁴, and 340 highlights the changing epidemiology of the pathogen that clinicians should be aware of. 341 342

Microsatellite typing in C. parapsilosis is typically performed using four loci and provides a 343 discriminatory power between 0.63³⁹ and 0.99²¹. The four loci MLST established in this study 344 achieved a discriminatory power of 0.87, within the range of what is achieved using microsatellite 345 markers. Importantly, the MLST methodology could unambiguously compare samples from >9 years 346 and around the world, a task not possible using existing microsatellite strategies based on gel 347 electrophoresis profiles. Moreover, it recapitulated whole genome-based phylogenetic relationships 348 with ~97% accuracy, demonstrating its use not only in outbreak tracking and epidemiology but in 349 phylogenetic contexts. Taken together, our study provides a high resolution description of a 350 fluconazole-resistant C. parapsilosis outbreak, identifies hospital transfers as recurring source of 351 352 pathogen introductions, and defines a sequence-based typing scheme for epidemiology and rapid 353 identification of potential outbreaks.

354

355 Methods

356 Outbreak cases and sample collection

The 68 novel strains of *C. parapsilosis* sequenced in this study were sent to the German National Reference Centre for Invasive Fungal Infections (NRZMyk) by German healthcare facilities and laboratories for species confirmation and susceptibility testing between 2014 and 2022 (Table 1). For tracking outbreak dynamics, admission and discharge records were obtained for all outbreak patients beginning January 2018, corresponding to one year before the first outbreak case, and extending to December 2022. Patient information was obtained from the sample submission form of the NRZMyk. Samples were de-identified via the assignment of an NRZ ID (e.g. NRZ-XXXX) which cannot be linked

to a patient, hospital, or region. The Ethics Committee of the University Hospital Jena approved this
 study under registration number 2024-3255-Daten.

366

Strains submitted to the NRZMyk from outside Berlin were selected for whole genome sequencing 367 (WGS) if they displayed resistance to one or more medical azole. For cities with azole resistant 368 samples selected for sequencing, an additional number of azole susceptible strains were included 369 from this city. In total 44 azole resistant strains (FLC^R, VOR^R, POS^S, or ITR^R) and 25 fully azole 370 susceptible strains were analyzed. Strains were identified as *C. parapsilosis* prior to WGS by Sanger 371 sequencing of the ITS locus. This locus was amplified with the forward primer V9G (5'-372 TTACGTCCCTGCCCTTTGTA-3') and the reverse primer LS266 (5'-373 GCATTCCCAAACAACTCGACTC-3). The resultina 374 sequences were compared against 375 C. parapsilosis sequences in the NCBI database using BLAST.

376

377 Antifungal susceptibility testing

378 In vitro antifungal susceptibility testing was performed by broth microdilution technique following the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standard methodology for the 379 following antifungals: fluconazole (FLC; Pfizer Inc., Peapack, NJ, USA), itraconazole (ITR, 380 Chemicalpoint, Deisenhofen, Germany), posaconazole (POS; MSD, Rahway, NJ, USA), and 381 voriconazole (VOR; Pfizer Inc., Peapack, NJ, USA). Minimum inhibitory concentration (MICs) were 382 assessed with a nephelometer (Labsystems Nepheloskan Ascent Microplate Reader Type 750) after 383 24 h of incubation at 35°C. The endpoint of growth was as a 50% inhibition in comparison with the 384 drug-free control. Reference strain C. parapsilosis ATCC 22019 was used as a quality control. 385

386 387

388 DNA extraction and genome sequencing

For extraction of genomic DNA, single colonies of each putative strain were isolated and grown 389 overnight on YPD plates at 35°C. Fungal material was transferred to a tube containing acid-washed 390 391 glass beads and lysis buffer (50 mM Tris, 50 mM sodium EDTA, 3% [wt/vol] sodium dodecyl sulfate 392 [SDS] [pH 8]). The samples were homogenized using a vortex adapter, followed by incubation in a 393 thermomixer. Next, cellular debris was pelleted by centrifugation, and the supernatant was transferred to a new tube. RNAse treatment was performed for 1h at 37°C. Subsequently, 3M sodium acetate 394 was added to the tube, samples were incubated at -20°C, then centrifuged and the supernatant 395 transferred to a new tube. DNA was then precipitated using EtOH and the resulting pellet washed 396 twice. DNA extracts that did not meet the requirement of purity were purified using the Monarch 397 genomic DNA purification kit (New England BioLabs Inc., Frankfurt a. M., Germany). Library 398 preparation and 2x250bp paired end sequencing was performed by GeneWiz using the Illumina 399 MiSeq platform. 400

- 401
- 402 Genome sequencing, quality control, alignment, and variant identification

Raw sequence reads were trimmed for quality using TrimGalore v0.6.6 in paired end mode using the 403 default error rate threshold of 0.1. Sequence data quality was assessed before and after trimming 404 using FastQC v0.11.9. Mapping to the CDC317 reference genome (FungiDB, release 50) was 405 performed using bwa-mem2 v2.2.1⁴⁰. Duplicates were marked using the MarkDuplicates function of 406 Picard v2.24.0. Alignment and genome coverage statistics 407 were assessed using CollectAlignmentMetrics and CollectWgsMetrics from the Picard tools (v2.24.0). Only samples with a 408 mean genome coverage of 10x and >90% of reads mapping to the CDC317 reference genome were 409 included in downstream analyses. Genome coverage and fraction of mapped reads for each sample 410 are listed in Supplemental File 1. Variant calling was performed using Freebayes v1.3.2-dirty. Variants 411 were filtered using vcffilter v0.2 and the following filter string: "QUAL > 30 & DP > 5 & SAF > 0 & SAR 412 > 0 & RPR > 1 & RPL > 1". Variants were annotated using snpEFF v5.1 41 and a custom database 413 made from the CDC317 reference genome files and using the alternative yeast nuclear and yeast 414 415 mitochondrial codon tables. For defining features within upstream and downstream regions, a cutoff of 500 bp was used. 416

417

418 <u>SNV-based phylogeny and identification of phylogenetic clusters</u>

For the phylogeny and SNV distance-based analyses, only variant positions with non-zero coverage 419 in all samples and SNVs were included. Variant positions with zero coverage, as well as all insertion 420 or deletion variants were removed from the vcf files. The resulting multi-sample VCF was converted 421 to a phylip alignment with a length of 38,567 positions. Pairwise SNV distances between isolates were 422 calculated using SNP Dist ⁴². A maximum-likelihood (ML) phylogeny was inferred by IQ-TREE 2 423 v2.2.0.3⁴³ using the GTR+ASC model to account for ascertainment bias as constant positions were 424 excluded. The ModelFinder module ⁴⁴ of IQ-TREE was used to confirm that GTR was also the best 425 fitting model based on Akaike and Corrected Akaike Information Criterion. The ERG11 amino acid 426 annotations on the phylogeny are reported relative to the C. parapsilosis reference genome CDC317, 427 except for cDNA position 395, corresponding to amino acid position 132. CDC317 is azole resistant 428 and contains a Y132F substitution relative to the EUCAST control strain ATCC 22019. Given this, 429 430 samples reporting no variant at position 395 of the CDS were re-coded to a Y132F amino acid 431 substitution and samples recording a 395T>A change relative to CDC317 were reported as not having an amino acid substitution at position 132. The annotated phylogenies were created using ggtree ⁴⁵. 432

433

Identification of phylogenetic clusters was performed using TreeCluster v1.0.3 ⁴⁶ using a cut threshold
 of 0.700. The identified clusters were labeled in accordance with the five major clades described in
 ³⁵. As TreeCluster calculated sufficient intraclade genetic distance to further subdivide clades 2 and
 4, clusters belonging to these clades were assigned the IDs of 2a, 2b and 4a-g.

438

439 Identification of discriminatory loci for sequence typing

Variant profiles of complete gene coding regions were obtained from vcf files and the number of distinct profiles present among the isolates calculated by hierarchical clustering analysis. Protein

it is made available under a CC-bT-INC-ND 4.0 International license.

coding regions with no discriminatory power were discarded and the top 212 CDS were further
 evaluated for their discriminatory power in 750 bp sliding windows with a step size of 50 bp. Windows
 including intronic sequence were excluded for downstream selection.

445

To ensure that potential sequence typing loci were present in the genomes of all samples as a single 446 copy, loci were screened for the presence of the presence of copy number variations (CNVs) using 447 Control-FREEC v11.6⁴⁷, DELLY v1.1.6⁴⁸, and CNVator v0.4.1⁴⁹. Multiple tools utilizing different 448 approaches for detecting copy number changes, including tools utilizing read depth, GC 449 normalization, and split read mapping, were used as many CNV calling software suffer from false 450 positives. DELLY and CNVator were run with default parameters. As FREEC uses GC normalization 451 which varies by organism, 0.25 was used for the minExpectedGC and 0.45 for maxExpectedGC. Loci 452 that fell within CNVs detected by two or more callers were excluded from further consideration. 453 454 Several samples from the publicly available data displayed prominent chromosome-end bias ⁵⁰. As this overrepresented coverage at the chromosome ends reduces confidence for CNV calling, these 455 456 samples were excluded from CNV analysis.

457

458 In silico strain typing

Locus sequence was extracted *in silico* from the vcf files using the consensus function of BCFtools v1.9 ⁵¹ and aligned using MUSCLE v3.8 via the R package msa. As BCFtools is not able to convert heterozygous sites to their corresponding IUPAC base, this was performed after alignment using an in-house R script. Concatenated alignments from the four loci were built into a maximum-likelihood phylogeny using RaxML (v2.0.10) using the GTR substitution model and 100 bootstrap replicates. The resulting phylogeny was visualized using ggtree ⁴⁵.

465

Hunter's discriminatory power was calculated using the following equation 52:

$$D = 1 - \frac{1}{N(N-1)} \sum_{j=1}^{s} x_j(x_j - 1)$$

468

469 PCR-amplification and Sanger sequencing of sequence typing markers

Primers for the selected loci were designed using NCBI Primer Blast and are listed in Table 3, along 470 with the predicted fragment size. PCR was performed using the following cycling parameters: 4 min 471 at 95°C, 40 cycles each consisting of a 45 sec denaturation at 95°C followed by 45 sec of annealing 472 at 57°C for CPAR2 808110 and CPAR2 212940 and 59°C for CPAR2 101470 and CPAR2 108720. 473 and an extension at 72°C for 2 min, and a final 10 min at 72°C. Sanger sequencing was performed 474 by LGC (Berlin, Germany). As our Sanger sequence data was not reported with IUPAC codes 475 representing heterozygous sites, these were manually corrected by manual review of the sequencing 476 477 chromatogram. We observed cases where the CPAR2 101470 sequencing reaction failed to cover

the entire amplicon when using the F primer, missing the final variant which we resolved by performing

a second Sanger reaction using the R strand. This affects the differentiation of clusters 2b and 2d.

480

481 Data availability

482 Raw FASTQ files for novel isolates sequenced in this study were uploaded to the NCBI Sequence

Read Archive and are publicly available under BioProject PRJNA996760. Accession numbers for

the publicly available sequence data used in this study are listed in Supplemental File 1. Genbank

- records for the Sanger sequencing of the MLST loci performed in this study are listed in
- 486 Supplemental Table 2.
- 487

488 <u>Acknowledgements</u>

We are grateful to Peggy Karanatsiou of the University of Jena and Philipp Hupel, Carmen Karkowski, and Christiane Weigel of the NRZMyk for technical assistance. We also thank MSD and Pfizer for

491 providing the drugs for antifungal susceptibility testing free of charge.

492

493 Funding

This project was supported by The Federal Ministry for Education and Science (Bundesministerium für Bildung und Forschung) within the framework of InfectControl 2020 (Projects FINAR 2.0, grant 03ZZ0834). The work of the German National Reference Center for Invasive Fungal Infections is supported by the Robert Koch Institute from funds provided by the German Ministry of Health (grant 1369-240). AEB is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research

- 499 358 Foundation) under Germany's Excellence Strategy EXC 20151 Project-ID 390813860.
- 500

501 <u>Authors' contributions</u>

AEB and GW conceptualized the study. PB, FRK, BG, RP, OK, GW and AEB contributed to investigation, methodology, and formal analysis. PB, GW, and AEB were responsible for visualization. AEB, PB, and GW were responsible for writing the original draft. All authors participated in reviewing and editing the manuscript.

506

507 Conflicts of Interest

508 The authors have no conflicts of interest to report.

509

510 **References**

- Mesini, A. *et al.* Changing epidemiology of candidaemia: Increase in fluconazole-resistant
 Candida parapsilosis. *Mycoses* 63, 361–368 (2020).
- 513 2. Tóth, R. *et al.* Candida parapsilosis: From genes to the bedside. *Clin. Microbiol. Rev.* 32, 1–38
 514 (2019).
- S15 3. Rhodes, J. & Fisher, M. C. Global epidemiology of emerging Candida auris. *Curr. Opin. Microbiol.* 52, 84–89 (2019).
- 517 4. Daneshnia, F. *et al.* Worldwide emergence of fluconazole-resistant Candida parapsilosis:

medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24302918; this version posted February 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

current framework and future research roadmap. Lancet Microbe 4, e470-e480 (2023). 518 5. Arastehfar, A. et al. Clonal Candidemia Outbreak by Candida parapsilosis Carrying Y132F in 519 520 Turkey: Evolution of a Persisting Challenge. Front. Cell. Infect. Microbiol. 11, (2021). 6. Branco, J. et al. Fluconazole and Voriconazole Resistance in Candida parapsilosis Is Conferred 521 by Gain-of-Function Mutations in MRR1 Transcription Factor Gene. Antimicrob. Agents 522 Chemother. 59, 6629-6633 (2015). 523 7. Branco, J. et al. Clinical azole cross-resistance in Candida parapsilosis is related to a novel 524 MRR1 gain-of-function mutation. Clin. Microbiol. Infect. 28, 1655.e5-1655.e8 (2022). 525 8. Daneshnia, F. et al. Determinants of fluconazole resistance and echinocandin tolerance in C. 526 527 parapsilosis isolates causing a large clonal candidemia outbreak among COVID-19 patients in a Brazilian ICU. Emerg. Microbes Infect. 11, 2264–2274 (2022). 528 9. Pinhati, H. M. S. et al. Outbreak of candidemia caused by fluconazole resistant Candida 529 parapsilosis strains in an intensive care unit. BMC Infect. Dis. 16, 4-9 (2016). 530 10. Qi, L. et al. Nosocomial outbreak of Candida parapsilosis sensu stricto fungaemia in a neonatal 531 intensive care unit in China. J. Hosp. Infect. 100, e246-e252 (2018). 532 11. Thomaz, D. Y. et al. An Azole-Resistant Candida parapsilosis Outbreak: Clonal Persistence in 533 the Intensive Care Unit of a Brazilian Teaching Hospital. Front. Microbiol. 9, (2018). 534 12. Arastehfar, A. et al. First report of candidemia clonal outbreak caused by emerging fluconazole-535 resistant Candida parapsilosis isolates harboring Y132F and/or Y132F+K143R in Turkey. 536 Antimicrob. Agents Chemother. (2020) doi:10.1128/AAC.01001-20. 537 13. Corzo-Leon, D. E., Peacock, M., Rodriguez-Zulueta, P., Salazar-Tamayo, G. J. & MacCallum, 538 D. M. General hospital outbreak of invasive candidiasis due to azole-resistant Candida 539 parapsilosis associated with an Erg11 Y132F mutation. Med. Mycol. 1-8 (2020) 540 doi:10.1093/mmy/myaa098. 541 14. Danilo Y. Thomaz, João N. de Almeida Jr. *, O. N. E. S., Gilda M.B. Del Negro, Gabrielle O. M. 542 H. Carvalho, V. M. F. G., Maria Emilia B. de Souza, Amir Arastehfar, Carlos H. Camargo, A. L., 543 Motta, Flávia Rossi, David S. Perlin, Maristela P. Freire, Edson Abdala, G., & Benard. 544 Environmental clonal spread of azole-resistant Candida parapsilosis with Erg11-Y132F mutation 545 causing a large candidemia outbreak in a Brazilian Cancer Referral Center. J. Fungi (2021). 546 15. Fekkar, A. et al. Hospital Outbreak of Fluconazole-Resistant Candida parapsilosis: Arguments 547 for Clonal Transmission and Long-Term Persistence. Antimicrob. Agents Chemother. 65, 548 e02036-20 (2021). 549 16. Guinea, J. et al. Whole genome sequencing confirms Candida albicans and Candida 550 parapsilosis microsatellite sporadic and persistent clones causing outbreaks of candidemia in 551 neonates. Med. Mycol. 60, myab068 (2022). 552 17. Thomaz, D. Y. et al. A Brazilian Inter-Hospital Candidemia Outbreak Caused by Fluconazole-553 Resistant Candida parapsilosis in the COVID-19 Era. J. Fungi 8, 100 (2022). 554 18. Trevijano-Contador, N. et al. Global emergence of resistance to fluconazole and voriconazole in 555 Candida parapsilosis in tertiary hospitals in Spain during the COVID-19 pandemic. Open Forum 556 Infect. Dis. ofac605 (2022) doi:10.1093/ofid/ofac605. 557 19. Hernández-Castro, R. et al. Outbreak of Candida parapsilosis in a neonatal intensive care unit: 558 A health care workers source. Eur. J. Pediatr. 169, 783–787 (2010). 559 20. Presente, S. et al. Hospital Clonal Outbreak of Fluconazole-Resistant Candida parapsilosis 560 Harboring the Y132F ERG11p Substitution in a French Intensive Care Unit. Antimicrob. Agents 561 Chemother. 67, e01130-22 (2023). 562 21. Sabino, R. et al. New polymorphic microsatellite markers able to distinguish among Candida 563 parapsilosis sensu stricto isolates. J. Clin. Microbiol. 48, 1677-1682 (2010). 564 22. Garcia-Hermoso, D., Desnos-Ollivier, M. & Bretagne, S. Typing Candida Species Using 565 Microsatellite Length Polymorphism and Multilocus Sequence Typing. in Candida Species: 566 Methods and Protocols (eds. Calderone, R. & Cihlar, R.) 199-214 (Springer, 2016). 567

568		doi:10.1007/978-1-4939-3052-4_15.
569	23.	de Valk, H. A., Meis, J. F. G. M. & Klaassen, C. H. W. Microsatellite based typing of Aspergillus
570		fumigatus: Strengths, pitfalls and solutions. J. Microbiol. Methods 69, 268–272 (2007).
571	24.	Hamprecht, A. et al. Candida auris in Germany and Previous Exposure to Foreign Healthcare.
572		Emerg. Infect. Dis. 25 , 1763–1765 (2019).
573	25.	Lockhart, S. R. et al. Simultaneous emergence of multidrug-resistant candida auris on 3
574		continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect.
575		<i>Dis.</i> 64 , 134–140 (2017).
576	26.	Rhodes, J. et al. Genomic epidemiology of the UK outbreak of the emerging human fungal
577		pathogen Candida auris article. Emerg. Microbes Infect. 7, (2018).
578	27.	Asadzadeh, M., Dashti, M., Ahmad, S., Alfouzan, W. & Alameer, A. Whole-Genome and
579		Targeted-Amplicon Sequencing of Fluconazole-Susceptible and -Resistant Candida
580		parapsilosis Isolates from Kuwait Reveals a Previously Undescribed N1132D Polymorphism in
581		CDR1. Antimicrob. Agents Chemother. 65, 10.1128/aac.01633-20 (2021).
582	28.	Arastehfar, A. et al. Candidemia Among Coronavirus Disease 2019 Patients in Turkey Admitted
583		to Intensive Care Units: A Retrospective Multicenter Study. Open Forum Infect. Dis. 9, ofac078
584		(2022).
585	29.	Kim, T. Y. et al. Evolution of Fluconazole Resistance Mechanisms and Clonal Types of Candida
586		parapsilosis Isolates from a Tertiary Care Hospital in South Korea. Antimicrob. Agents
587		Chemother. 66, e00889-22 (2022).
588	30.	Demirci-Duarte, S., Arikan-Akdagli, S. & Gülmez, D. Species distribution, azole resistance and
589		related molecular mechanisms in invasive Candida parapsilosis complex isolates: Increase in
590		fluconazole resistance in 21 years. Mycoses 64, 823–830 (2021).
591	31.	Díaz-García, J. et al. Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes
592		Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p
593		Substitution. Antimicrob. Agents Chemother. 66, e00710-22 (2022).
594	32.	Grossman, N. T., Pham, C. D., Cleveland, A. A. & Lockhart, S. R. Molecular Mechanisms of
595		Fluconazole Resistance in Candida parapsilosis Isolates from a U.S. Surveillance System.
596		Antimicrob. Agents Chemother. 59, 1030–1037 (2015).
597	33.	Berkow, E. L. et al. Multidrug Transporters and Alterations in Sterol Biosynthesis Contribute to
598		Azole Antifungal Resistance in Candida parapsilosis. Antimicrob. Agents Chemother. 59, 5942-
599		5950 (2015).
600	34.	Asadzadeh, M., Ahmad, S., Al-Sweih, N. & Khan, Z. Epidemiology and Molecular Basis of
601		Resistance to Fluconazole Among Clinical Candida parapsilosis Isolates in Kuwait. Microb.
602		Drug Resist. 23, 966–972 (2017).
603	35.	Bergin, S. A. et al. Systematic Analysis of Copy Number Variations in the Pathogenic Yeast
604		Candida parapsilosis Identifies a Gene Amplification in RTA3 That is Associated with Drug
605		Resistance. <i>mBio</i> 13 , e01777-22 (2022).
606	36.	Wang, H. et al. Investigation of an unrecognized large-scale outbreak of Candida parapsilosis
607		sensu stricto fungaemia in a tertiary-care hospital in China. Sci. Rep. 6, 27099 (2016).
608	37.	Chow, N. A. et al. Multiple introductions and subsequent transmission of multidrug-resistant
609		Candida auris in the USA: a molecular epidemiological survey. Lancet Infect. Dis. 3099, 1–8
610		(2018).
611	38.	Chow, N. A. et al. Tracing the evolutionary history and global expansion of Candida auris using
612		population genomic analyses. <i>mBio</i> 11 , 2020.01.06.896548 (2020).
613	39.	Romeo, O. et al. Microsatellite-based genotyping of Candida parapsilosis sensu stricto isolates
614		reveals dominance and persistence of a particular epidemiological clone among neonatal
615		intensive care unit patients. Infect. Genet. Evol. 13, 105–108 (2013).
616	40.	Vasimuddin, Md., Misra, S., Li, H. & Aluru, S. Efficient Architecture-Aware Acceleration of BWA-
617		MEM for Multicore Systems. in 2019 IEEE International Parallel and Distributed Processing

medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24302918; this version posted February 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 618 *Symposium (IPDPS)* 314–324 (2019). doi:10.1109/IPDPS.2019.00041.
- 41. Cingolani, P. *et al.* A program for annotating and predicting the effects of single nucleotide
 polymorphisms, SnpEff. *Fly (Austin)* 6, 80–92 (2012).
- 42. Seemann, T. Pairwise SNP distance matrix from a FASTA sequence alignment.
 https://github.com/tseemann/snp-dists (2018).
- 43. Minh, B. Q. *et al.* IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol. Biol. Evol.* **37**, 1530–1534 (2020).
- 44. Kalyaanamoorthy, S., Minh, B. Q., Wong, T. K. F., von Haeseler, A. & Jermiin, L. S.
 ModelFinder: fast model selection for accurate phylogenetic estimates. *Nat. Methods* 14, 587– 589 (2017).
- 45. Yu, G., Smith, D. K., Zhu, H., Guan, Y. & Lam, T. T.-Y. ggtree: an r package for visualization
 and annotation of phylogenetic trees with their covariates and other associated data. *Methods Ecol. Evol.* 8, 28–36 (2017).
- 46. Balaban, M., Moshiri, N., Mai, U., Jia, X. & Mirarab, S. TreeCluster: Clustering biological
 sequences using phylogenetic trees. *PLOS ONE* 14, e0221068 (2019).
- 47. Boeva, V. *et al.* Control-FREEC: a tool for assessing copy number and allelic content using
 next-generation sequencing data. *Bioinformatics* 28, 423–425 (2012).
- 48. Rausch, T. *et al.* DELLY: structural variant discovery by integrated paired-end and split-read analysis. *Bioinformatics* **28**, i333–i339 (2012).
- 49. Abyzov, A., Urban, A. E., Snyder, M. & Gerstein, M. CNVnator: An approach to discover,
 genotype, and characterize typical and atypical CNVs from family and population genome
 sequencing. *Genome Res.* 21, 974–984 (2011).
- 50. Abbey, D. A. *et al.* YMAP: a pipeline for visualization of copy number variation and loss of
 heterozygosity in eukaryotic pathogens. *Genome Med.* 6, 100 (2014).
- 51. Danecek, P. et al. Twelve years of SAMtools and BCFtools. *GigaScience* **10**, giab008 (2021).
- 52. Hunter, P. R. Reproducibility and indices of discriminatory power of microbial typing methods. *J. Clin. Microbiol.* 28, 1903–1905 (1990).

645

Figures 646







Figure 1. Timeline and hospital network dynamics of a Candida parapsilosis outbreak in 648 Berlin, Germany. (a) Timeline histogram of the 33 outbreak cases. Dates are taken from the date 649 of first positive culture. Color indicates the inpatient hospital at the time of isolation. A single case 650 was identified in an ambulatory patient, which is indicated with "NA" for the inpatient hospital. (b) 651 Inpatient stays of the outbreak cases represented as a network, where nodes (large circles) 652 represent hospitals in the Berlin area and edges (lines) represent direct or indirect patient transfers 653 654 between two institutions. Edge thickness depicts the relative number of transfers between two nodes. Individual patient case numbers are indicated within the node and along the edge. For the 655 network, admission and discharge data beginning 12 months prior to the first detected outbreak and 656 657 extending until the end of 2022 was utilized.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24302918; this version posted February 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

658



659

Figure 2. Whole genome phylogeny of Candida parapsilosis isolates from a global 660 distribution and their azole susceptibility profiles and ERG11 polymorphisms. Maximum-661 likelihood phylogeny constructed from SNV data from 38,567 variable positions. Tree is shown 662 rooted at the midpoint. To increase tree readability, samples from the same sequencing study that 663 664 showed little genetic differentiation were randomly downsampled to a maximum of 4 samples per sequencing project - with the exception of the samples from the samples described for the first time 665 in our study. Branches are supported by ultrafast bootstrap values of >0.95 unless otherwise 666 667 indicated. Where available, azole susceptibility data relative to EUCAST breakpoints and ERG11 polymorphisms are indicated. Strains that were resistant to one or more azole but where no 668 polymorphisms in ERG11 were detected are marked with an asterisk. 669



670

Figure 3. SNV matrix of the German isolates sequenced in this study. 671

Heatmap showing the pairwise SNV differences between the novel German isolates described in 672

673 this study. Metadata bands indicate (from top to bottom): fluconazole susceptibility, year of sample

isolation, and whether the sample is from the city of Berlin (including both outbreak and non-674

outbreak strains) or another city in Germany. 675



676

Figure 4. Comparison of whole genome and four loci phylogenies of C.parapsilosis. (a-b) 677

- 678 Maximum-likelihood whole genome SNV phylogeny with tips colored by country of origin (a) or
- genetic cluster based on whole-genome data (b). (c) Maximum-likelihood phylogeny constructed 679
- 680 from ~700 bp of sequence from CPAR2 101470, CPAR2 108720, CPAR2 212940, and
- CPAR2 808110. Tip color indicates the genetic cluster samples were assigned based on the whole 681
- genome phylogeny in panel b. 682

Table 1. Patient characteristics, isolate sources, and MIC data for the newly-described and sequenced German C. parapsilosis isolates in this study.

	Outbreak (n = 33)	Non-outbreak (n = 38)
Patient		
Sex F	15 (45.5%)	-
Age (years)	Mean 68 (range 33 - 83)	-
Source		
Wound	12 (38.7%)	5 (13.2%)
Central venous catheter	9 (29.0%)	7 (18.4%)
Urine	5 (16.1%)	0 (0.0%)
Blood	2 (6.5%)	17 (44.7%)
Other	3 (9.7%)	9 (23.7%)
MIC (mg/l)		Median (Min - Max)
Fluconazole	64 (16 - >64)	1 (0.25 - >64)
Voriconazole	1 (0.25 - 4)	0.03 (≤0.016 - 8)
Posaconazole	0.03 (≤0.016 - 0.25)	≤0.016 (≤0.016 - 0.5)
Itraconazole	0.125 (≤0.016 - 0.5)	0.125 (≤0.016 - 1)
Isavuconazole	≤0.016 (≤0.016 - 0.125)	≤0.016 (≤0.016 - 2)
Anidulafungin	1 (0.5 - 4)	1 (0.5 - 2)
Amphotericin B	0.5 (0.25 - 1)	0.5 (0.06 - 1)

Table 2. Loci used for Candida parapsilosis sequence typing. 687

688

Gene	Chromosome	Position	Predicted Function	<i>C. albicans</i> Ortholog
CPAR2_101470	Contig005569	298860- 299861	Structural constituent of cytoskeleton Mitotic spindle orientation Nuclear migration	orf19.3976 (<i>JNM1</i>)
CPAR2_108720	Contig005569	1835814- 1833166	Cellular response to heat Fungal-type cell wall organization	orf19.3038 (<i>TPS2</i>)
CPAR2_212940	Contig005809	2776693- 2775623	Nucleotide binding Oxidoreductase activity	orf19.2036 (<i>DDD1</i>)
CPAR2_808110	Contig005807	1878755- 1876554	Ferric-chelate reductase activity Copper ion import Iron ion transport Plasma membrane	orf19.1932 (<i>CFL4</i>)

689 Gene IDs, genomic coordinates, and descriptions of the four target genes selected for sequence typing. 690 Rightmost column includes the orthologous ORF in Candida albicans.

692

Table 3. Oligo sequences for amplification and sequencing of Candida parapsilosis typing loci. 693

Oligo ID	Seq?	Sequence	Gene position	Amplicon size
CPAR2_101470_F	Х	GTGTGTCAACAACGGAGCAT	(-15) - 680	695 bp
CPAR2_101470_R		CATTTTTGGGGACTGGCACA		
CPAR2_108720_F	Х	GGAAACCAATCTTGTCAGCACC	1891 - 2592	701 bp
CPAR2_108720_R		ACATCCATGCGGTATCTCCG		
CPAR2_212940_F		TAGTATACAAATGGTACACAATCGC	(-7) - 818	825 bp
CPAR2_212940_R	Х	TCTGGATGTGGACGTGGTTT		
CPAR2_808110_F		AGTTGAGTCGTTATCTGAGGTTAG	265 - 1022	757 bp
CPAR2_808110_R	х	TTGCTGGTACTTGGGTGC		

695 Table of forward and reverse primers used for the amplification of the four loci selected during this study. The 696 oligo used for subsequent Sanger sequencing is indicated in the 'Seq' column. Gene positions are relative to the first coding base in the reference genome of CDC317. 697

698

⁶⁹¹







Supplemental Figure 1. Whole genome phylogeny of Candida parapsilosis isolates from 701

Germany, their fluconazole susceptibility, and ERG11 polymorphisms. Maximum-likelihood 702

phylogeny constructed from SNV data from 38,567 variable positions. Tree is shown rooted at the 703

midpoint. Tip colors indicate the city where the isolate originated from. Fluconazole resistant isolates 704

where no polymorphisms in ERG11 were detected are marked with an asterisk. 705



is indicated in the yellow box. Coverage depth was calculated as reads per million (RPM).

Supplemental Table 1. Genetic variants observed in resistance-associated genes among 712

713 azole-resistant isolates lacking ERG11 Y132 substitution.

	NRZ- 2016-333	NRZ- 2018-148	NRZ- 2019-030	NRZ- 2019-337	NRZ- 2019-498	NRZ- 2020-725	NRZ- 2021-0166	NRZ- 2021-0782
CPAR2_304370 (CDR1b)	P70fs	A1214V		R224*				
CPAR2_301760 (MDR1)			W104*					
CPAR2_603010 (MDR1b)		G247R		L236F				
CPAR2_207540 (MDR1)		F463I						Т307К
CPAR2_303510 (TAC1)		Y792fs		L518F				
CPAR2_807270 (MRR1)					G583E		S629G	N725Y
CPAR2_207280 (UPC2)							N455D	
CPAR2_212210 (ALD5)								T18N
CPAR2_401350 (DAG7)							P77fs	
CPAR2_405010 (ERG6)								C300Y

Abbreviations in addition to standard one-letter amino acid codes: fs = frameshift; * = nonsense 714

mutation (premature stop codon). 715

716 Supplemental Table 2. C. parapsilosis strains used for laboratory validation of sequence

typing markers as well as their genetic cluster and sequence type identity and GenBank 717

accession number for the Sanger data generated from each sample. 718

<i>C. parapsilosis</i> strain ID	Sequence type	GenBank accession				
		CPAR2_101470	CPAR2_108720	CPAR2_212940	CPAR2_808110	
NRZ-2016-033	ST 16 (0-0-0-0)	OR413203	OR413216	OR413229	OR413242	
NRZ-2018-148	ST 24 (0-0-1-4)	OR413204	OR413217	OR413230	OR413243	
NRZ-2018-167	ST 28 (3-0-3-10)	OR413205	OR413218	OR413231	OR413244	
NRZ-2019-030	ST 08 (1-0-2-7)	OR413206	OR413219	OR413232	OR413245	
NRZ-2019-074	ST 01 (4-6-4-7)	OR413207	OR413220	OR413233	OR413246	
NRZ-2019-077	ST 18 (0-0-0-1)	OR413208	OR413221	OR413234	OR413247	
NRZ-2019-337	ST 22 (0-0-0-4)	OR413209	OR413222	OR413235	OR413248	
NRZ-2019-498	ST 27 (3-4-3-8)	OR413210	OR413223	OR413236	OR413249	
NRZ-2019-532	ST 18 (0-0-0-1)	OR413211	OR413224	OR413237	OR413250	
NRZ-2019-747	ST 18 (0-0-0-1)	OR413212	OR413225	OR413238	OR413251	
NRZ-2020-315	ST 23 (0-0-0-5)	OR413213	OR413226	OR413239	OR413252	
NRZ-2020-540	ST 18 (0-0-0-1)	OR413214	OR413227	OR413240	OR413253	
NRZ-2020-726	ST 01 (4-6-4-7)	OR413215	OR413228	OR413241	OR413254	
NRZ-2021-0591	ST 18 (0-0-0-1)	OR987460	OR987469	OR987478	OR987451	
NRZ-2022-0323	ST 18 (0-0-0-1)	OR987461	OR987470	OR987479	OR987452	
NRZ-2022-0798	ST 18 (0-0-0-1)	OR987462	OR987471	OR987480	OR987453	
NRZ-2023-0851	ST 18 (0-0-0-1)	OR987454	OR987463	OR987472	OR987445	
NRZ-2023-0852	ST 18 (0-0-0-1)	OR987455	OR987464	OR987473	OR987446	
NRZ-2023-0854	ST 18 (0-0-0-1)	OR987456	OR987465	OR987474	OR987447	
NRZ-2023-0850	ST 18 (0-0-0-1)	OR987457	OR987466	OR987475	OR987448	
NRZ-2023-0853	ST 18 (0-0-0-1)	OR987458	OR987467	OR987476	OR987449	
NRZ-2023-0855	ST 18 (0-0-0-1)	OR987459	OR987468	OR987477	OR987450	

719

720

Supplemental File 1. Accession numbers for the publicly available genomes analyzed in this 721 study and strain information for the outbreak strains described in this study. 722

723

Supplemental File 2. FASTA alignments of the four typing loci containing representative 724 sequence for each of the 31 sequence types. 725